Serenex and GlaxoSmithKline have agreed to a new drug research contract under which proteome mining technology from Serenex will be used in conjunction with GSK compounds.

GSK scientists from around the world will submit compounds to Serenex for analysis, the companies said in a statement.

Terms of the deal were not disclosed.

“The structure of this agreement will enable Serenex to more fully apply its technology to a larger number of GSK programs,” said Richard Kent, CEO of Serenex, in a statement. “Knowledge of a how compounds interact with multiple targets is important in understanding a drug candidate’s potential as an effective treatment for a particular disease.”

Serenex has developed proprietary technology based on proteomics that is used for its own drug compound research and by other clients such as GSK.